Unknown

Dataset Information

0

Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma.


ABSTRACT:

Background

Metastatic melanoma is a severe disease with one of the highest mortality rate in skin diseases. Overall survival has significantly improved with immunotherapy and targeted therapies. Kinase inhibitors targeting BRAF V600 showed promising results. BRAF genotyping is mandatory for the prescription of anti-BRAF therapies.

Methods

Fifty-nine formalin-fixed paraffin-embedded melanoma samples were assessed using High-Resolution-Melting (HRM) PCR, Real-time allele-specific amplification (RT-ASA) PCR, Next generation sequencing (NGS), immunohistochemistry (IHC) and the fully-automated molecular diagnostics platform IdyllaTM. Sensitivity, specificity, positive predictive value and negative predictive value were calculated using NGS as the reference standard to compare the different assays.

Results

BRAF mutations were found in 28(47.5%), 29(49.2%), 31(52.5%), 29(49.2%) and 27(45.8%) samples with HRM, RT-ASA, NGS, IdyllaTM and IHC respectively. Twenty-six (81.2%) samples were found bearing a c.1799T>A (p.Val600Glu) mutation, three (9.4%) with a c.1798_1799delinsAA (p.Val600Lys) mutation and one with c.1789_1790delinsTC (p.Leu597Ser) mutation. Two samples were found bearing complex mutations.

Conclusions

HRM appears the less sensitive assay for the detection of BRAF V600 mutations. The RT-ASA, IdyllaTM and IHC assays are suitable for routine molecular diagnostics aiming at the prescription of anti-BRAF therapies. IdyllaTM assay is fully-automated and requires less than 2 minutes for samples preparation and is the fastest of the tested assays.

SUBMITTER: Harle A 

PROVIDER: S-EPMC4844167 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma.

Harlé Alexandre A   Salleron Julia J   Franczak Claire C   Dubois Cindy C   Filhine-Tressarieu Pierre P   Leroux Agnès A   Merlin Jean-Louis JL  

PloS one 20160425 4


<h4>Background</h4>Metastatic melanoma is a severe disease with one of the highest mortality rate in skin diseases. Overall survival has significantly improved with immunotherapy and targeted therapies. Kinase inhibitors targeting BRAF V600 showed promising results. BRAF genotyping is mandatory for the prescription of anti-BRAF therapies.<h4>Methods</h4>Fifty-nine formalin-fixed paraffin-embedded melanoma samples were assessed using High-Resolution-Melting (HRM) PCR, Real-time allele-specific am  ...[more]

Similar Datasets

| S-EPMC6695223 | biostudies-literature
| S-EPMC3893431 | biostudies-literature
| S-EPMC5464614 | biostudies-literature
| S-EPMC6853954 | biostudies-literature
| S-EPMC3415711 | biostudies-other
| S-EPMC10090439 | biostudies-literature
| S-EPMC6595071 | biostudies-literature
| S-EPMC6392303 | biostudies-literature
| S-EPMC4744157 | biostudies-literature
| S-EPMC10685400 | biostudies-literature